Clinical evaluation of transfusion of prestorage-leukoreduced apheresis platelets.
With increased use of platelet concentrate (PC) in recent years, adverse reactions to PC transfusion have received much clinical attention. Most of these reactions stem from white blood cells (WBC) contaminating the transfused PC. Several are thought to be preventable by removing WBC before PC storage.


METHODS
We routinely filtered apheresis PC either during collection or immediately afterwards and monitored various indicators of platelet quality during storage. After transfusion to patients, transfusion efficacy and the type, severity, and frequency of posttransfusion side effects were compared with those of a control group in which PC was filtered at the bedside.


RESULTS
Prestorage-filtered PC contained an average of 3.1+/-0.7 x 10(11) platelets and 0.9+/-1.2 x 10(6) contaminating leukocytes. Measurement of platelet function and metabolic indicators revealed normal values throughout the storage period. CD62 measurement revealed no undue platelet activation after filtration or during the storage period. Cytokine, histamine, bradykinin, and complement levels showed no significant increase after filtration or during storage. Transfusion efficacy and overall side effect incidence rates were similar for the prestorage- and bedside-filtered groups, but reactions of the bedside-filtered group included serious reactions such as breathing difficulties and shock. No serious reactions were noted in the prestorage-filtered group.


CONCLUSIONS
Filtering PC before storage has no adverse effect on PC quality and may reduce the severity of post transfusion side effects.
Osaka-fu Kitaosaka Red Cross Blood Center, Kansai Medical University, Osaka, Japan.
Y
Y
Ogawa
M
M
Wakana
K
K
Tanaka
K
K
Oka
H
H
Aso
M
M
Hayashi
T
T
Seno
T
T
Ishida
S
S
Nomura
S
S
Fukuhara
D001792:Blood Platelets / Q000502:physiology; D001793:Blood Preservation / Q000379:methods; D002469:Cell Separation / Q000379:methods*; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000097:blood; D007958:Leukocyte Count; D007962:Leukocytes / Q000166:cytology; D008297:Male; D015539:Platelet Activation / Q000502:physiology; D010976:Platelet Count; D017713:Platelet Transfusion / Q000009:adverse effects; D010983:Plateletpheresis / Q000379:methods*
D007155:Immunologic Factors